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SLC30A8 encodes zinc transporter 8 which is involved in packaging and release of insulin. Evidence for the association of SLC30A8
variants with type 2 diabetes (T2D) is inconclusive. We interrogated single nucleotide polymorphisms (SNPs) around SLC30A8
for association with T2D in high-risk, pedigreed individuals from extended Mexican American families. This study of 118 SNPs
within 50 kb of the SLC30A8 locus tested the association with eight T2D-related traits at four levels: (i) each SNP using measured
genotype approach (MGA); (ii) interaction of SNPs with age and sex; (iii) combinations of SNPs using Bayesian Quantitative Trait
Nucleotide (BQTN) analyses; and (iv) entire gene locus using the gene burden test. Only one SNP (rs7817754) was significantly
associated with incident T2D but a summary statistic based on all T2D-related traits identified 11 novel SNPs. Three SNPs and one
SNP were weakly but interactively associated with age and sex, respectively. BQTN analyses could not demonstrate any informative
combination of SNPs over MGA. Lastly, gene burden test results showed that at best the SLC30A8 locus could account for only
1-2% of the variability in T2D-related traits. Our results indicate a lack of association of the SLC30A8 SNPs with T2D in Mexican
American families.

1. Introduction
Genome-wide association studies in humans and knockout
studies in mice have increasingly pointed towards an important role of the ZnT8 zinc transporter in pathogenesis of
type 2 diabetes (T2D) [1–6]. Since the publication of the first
association reports in 2007, several other studies testing the
association of the variants in the SLC30A8 gene that encodes
the ZnT8 transporter and the risk of T2D have been reported.
A recent meta-analysis examined evidence for the association
of the most intensely scrutinized polymorphism (rs13266634)
in SLC30A8 and found that the risk allele is associated with
a 16.5% increased risk of T2D in a dose-dependent manner
[7]. Corroborating the human research, studies in knockout
mice have also demonstrated that the ZnT8 protein is vital in
the process of 𝛽-cell secretion as well as hepatic clearance of
insulin [5, 6].

There is a strong biological basis to the hypothesized association between SLC30A8 variants and T2D. At the cellular
level, a critical step in the release of insulin from 𝛽 cells in the
pancreas is proper packaging of proinsulin into the secretory
granules [8]. This process is electrochemically facilitated and
requires the presence of Zn2+ and Ca2+ ions which form complexes with hexamers of proinsulin in the secretory granules
[9–11]. The Zn2+ ions required for this process are transported
across electrical gradient by the zinc transporter 8 (ZnT8)
protein [12]. This transporter is abundant in 𝛽 cells but has
also been observed in 𝛼 cells that orchestrate the release of
glucagon [13]. Together, the biological and implied clinical
underpinnings place SLC30A8 at a strategic position in the
continued quest for identifying key drug targets to treat T2D.
Despite the perceived importance of this gene in T2D
pathogenesis, however, observational evidence in this regard
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remains inconclusive. First, a large recent study demonstrated
that loss-of-function mutations in SLC30A8 afforded a surprising protection against T2D [14]. As a result, the exact
mechanism by which SLC30A8 may partake in T2D pathogenesis is unknown. Second, Cheng et al. [7] demonstrated in
a recently published meta-analysis that the published studies
associating rs13266634 with T2D are significantly heterogeneous (𝐼2 62%, 𝑝 < 0.001). This heterogeneity indicates that
the results are unlikely to be generalizable. Indeed, ethnic
differences among populations explain a substantial degree of
this heterogeneity [7]. Third, Rutter and Chimienti [15] argue
that factors such as age and hypoxic 𝛽 cell stress can modify
the association of SLC30A8 variants with T2D. In the light
of these and other [13, 16] contradictory findings, the role of
SLC30A8 in T2D is far from being well-understood.
Aside from one study [17] that formally tested for association of SLC308A variants with T2D-related traits, there is
a paucity of data on this potential association in individuals
with Mexican American ethnic background. We therefore
sought to investigate the specific association of several single
nucleotide polymorphisms (SNPs) in and around SLC308A
in the high-risk settings of Mexican American families. Data
for this study come from the high-resolution genotyping of
pedigreed individuals recruited in the San Antonio Family
Heart Study (SAFHS) [18–20]. Using rich genotyping data
and robust statistical techniques suited for family studies, we
demonstrate that the SLC30A8 locus is not associated with
differential T2D risk in the study population.

2. Materials and Methods
2.1. Study Participants. The initial SAFHS cohort consisted
of 1,431 individuals from 42 large and extended pedigrees.
Of these, high-density genotyping as well as other relevant
phenotypic data was available for a maximum of 1,383
individuals. The SAFHS also included a longitudinal arm
in which participants were followed up for development of
incident T2D. Complete follow-up information was available
on 913 individuals for a total follow-up of 11,049.92 personyears. The characteristics of the study population are shown
in Table 1. The Institutional Review Board of the University
of Texas Health Science Center at San Antonio approved the
study. A written informed consent was obtained from all the
study participants.
2.2. Phenotypic Traits. We included eight (two discrete and
six continuous) phenotypic traits related to T2D. The discrete
traits were: ever diabetes, defined as either presence of T2D
at baseline or de novo development of T2D during follow-up,
and incident diabetes, new cases of T2D during follow-up. For
these traits, T2D was defined using the American Diabetes
Association Clinical Practice Recommendations 2004 (fasting plasma glucose level ≥126 mg/dL [7.0 mmol/L], plasma
glucose ≥200 mg/dL [11.1 mmol/L] at 2 h after oral glucose
challenge, or both) [21]. Also, individuals were considered to
have diabetes if they reported use of antidiabetic medication
[22]. The six continuous traits were fasting glucose; fasting
insulin; 2-hour postprandial glucose; 2-hour postprandial
insulin; homeostatic model of assessment-insulin resistance
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(HOMA-IR); and homeostatic model of assessment, beta
(HOMA-𝛽). HOMA-IR values were calculated according
to the formula (fasting glucose [mmol/L] × fasting insulin
[𝜇U/mL]/22.5), while HOMA-𝛽 was calculated as (20x fasting insulin [𝜇U/mL])/(fasting glucose [mmol/L] − 3.5) [23].
Additional clinical variables measured were age, sex, waist
circumference, body mass index, systolic and diastolic blood
pressure, fasting and 2-hour plasma glucose, fasting insulin,
total serum cholesterol, serum triglycerides, high-density
lipoprotein (HDL) cholesterol, and use of lipid-lowering
and antihypertensive drugs. Methods used to measure these
variables have been described in detail previously [18–20].
2.3. High-Density Genotyping. Study participants were previously genotyped for approximately 995,321 SNP markers using several Illumina genotyping arrays, including
the HumanHap550v3, HumanExon510Sv1, Human1Mv1, and
Human1M-Duov3. Details of the data cleaning and imputing
steps for the genotypic data have been detailed elsewhere
[24]. We used all the SNPs within the SLC30A8 gene as well
those within 50 kb upstream and downstream of this gene. A
total of 118 SNPs were found in this region. Detailed characteristics along with genomic locations of these 118 SNPs are
provided in Supplementary Table 1 in Supplementary Material available online at http://dx.doi.org/10.1155/2016/6463214.
The variants were annotated using ANNOVAR [25] that used
human genome Build 19 and SNP version 138 databases for
annotation.
2.4. Statistical Analyses. We conducted the genotype-phenotype associations at four levels: each SNP considered one at a
time; potential interaction of the SNPs with age and sex; most
informative combinations of significantly associated SNPs
and association burden associated with the entire locus. All
associations were tested under the framework of the variance
components that allows partitioning of the total phenotypic
variance into components of interest while accounting for
kinship among individuals.
2.4.1. Measured Genotype Analyses (MGA). To evaluate the
association of each SNP with T2D-related traits we used the
MGA approach. This approach assumes that the likelihood
of observing measured genotype of a single locus and the
phenotypes within a family is a function of the measured
genotypes times the conditional likelihood of the phenotypes
[26]. To correct for multiple testing we used the method of
Li and Ji [27] since there was a substantial degree of linkage disequilibrium among these SNPs (Supplementary Figure 1). In all association analyses, ever diabetes and incident
diabetes were used as discrete traits while all the continuous
traits were inverse-normalized to ensure normal distribution
with a mean of zero and standard deviation of unity. All
association models were also adjusted for age, age2 , sex, age ×
sex interaction, age2 × sex interaction, and top four principal
components that captured ancestry-based population admixture. To detect a pattern of associations of the SNPs with all
the T2D-related traits, we computed a summary probability
score (PS) defined as ∑𝑡 −log10 𝑝, where 𝑡 is the phenotypic
trait and 𝑝 is the significance value.
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Table 1: Clinical characteristics of the SAFHS included in this study (𝑛 = 1, 383).
Characteristic
Age at enrolment (y)
Females
Waist (cm)
Central obesity (waist circumference ≥102 cm for males and ≥88 cm for females)
Body mass index (BMI, Kg/m2 )
Obesity (BMI ≥ 30 Kg/m2 )
Systolic blood pressure (SBP, mmHg)
Diastolic blood pressure (DBP, mmHg)
Hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg)
Type 2 diabetes
Prevalent T2D at baseline visit
Incident T2D detected during follow-up†
Ever T2D
Fasting glucose (mmol/L)†
2-hour postchallenge glucose (mmol/L)†
Fasting insulin†
2-hour postchallenge insulin†
HOMA-IR†
HOMA-𝛽†
Total serum cholesterol (mg/dL)
Serum triglycerides (mg/dL)
HDL cholesterol (mg/dL)
Medication use at baseline
Antihypertensive medications
Lipid lowering medications

𝑁∗
1,383
1,383
1,371
1,371
1,372
1,372
1,372
1,372
1,372
1,383
913
1,383
1,171
1,143
1,153
1,115
1,153
1,153
1,379
1,379
1,378

Description∗∗
39.17 (0.45)
822 (59.43)
94.71 (0.47)
641 (46.75)
29.24 (0.18)
531 (38.70)
120.38 (0.51)
70.67 (0.28)
247 (18.00)
169 (20.58)
208 (15.04)
149 (16.32)
357 (25.81)
4.82 (0.02)
5.61 (0.05)
14.11 (0.46)
76.86 (2.19)
3.16 (0.13)
19.38 (1.67)
189.27 (1.06)
150.10 (3.48)
50.14 (0.35)

1,376
1,376

132 (9.59)
25 (1.82)

∗

Number of individuals for whom data was available.
Numbers indicate mean (SE) for continuous variables and 𝑛 (%) for categorical variables.
†
These variables are reported only for individuals who did not have T2D at baseline.
∗∗

2.4.2. Interactions of SNPs with Age and Sex. Interaction of
each SNP with age and sex was conducted using a polygenic
modeling approach. In these models, age was binarized based
on <45 yrs or ≥45 yrs and sex was used as two nominal categories. Interactive models used SNP dosages multiplied by
age and sex, respectively. Statistical significance for interaction terms was evaluated by constraining the interaction term
to zero and calculating likelihood ratio statistic as two times
the difference in the log-likelihoods of the constrained and
unconstrained models. Statistical significance was tested at a
liberal global type 1 error rate of 0.2 before applying the correction for multiple testing using the method of Li and Ji [27].
2.4.3. Bayesian Quantitative Trait Nucleotide (BQTN) Analyses. Finding important combinations of key SNPs for the
T2D-related traits was facilitated using the Bayesian Quantitative Trait Nucleotide Analyses. The BQTN model developed
by Blangero et al. [28] is a Bayesian one that uses the underlying measured genotype model and conducts joint analysis
of multiple variants. It evaluates a series of combinations of
the candidate SNPs by comparing them to a base model.
Typically, if there are 𝑠 SNPs being evaluated then the total
number of models tested is 2𝑠 . Selection of the best model

is accomplished using the Bayesian Information Criterion
(BIC) which is defined for 𝑘th model as BIC𝑘 = −∧𝑘0 +
df𝑘 ln 𝑁𝑒 . In this equation, ∧𝑘0 is the likelihood ratio test
statistic comparing the QTN model with the null model; df𝑘
are the degrees of freedom and 𝑁𝑒 is the effective sample size.
The model with least BIC is considered as the best model.
2.4.4. Gene Burden Test. To quantify the contribution of all
the SLC30A8-associated SNPs to T2D-related traits, we made
use of the gene burden test [29]. For using this procedure, we
first transformed gene-specific polymorphism dosages into
a covariance matrix and converted this to a gene-specific
matrix of empirical kinship coefficients. This matrix was used
to extract the contribution to overall phenotypic variance
2
2
(2Φℎ𝑟2 + 2Eℎgeff
+
using the following equation: Ω = 𝜎Phenotypic
2
2
I𝑒 ). In this equation, Ω is the covariance matrix; 𝜎Phenotypic is
the total phenotypic variance of the trait; Φ and E represent
matrices of theoretical and empirical kinship expectations,
2
, and 𝑒2 represent the proportion of
respectively; ℎ𝑟2 , ℎgeff
phenotypic variance explained by residual additive effect of
polygenes, a gene-specific effect and a random environmental
effect, respectively; and I is the identity matrix. The signif2
component was tested using a likelihood
icance of the ℎgeff

4
ratio test statistic that is distributed as a 1/2 : 1/2 mixture
of a 1 degree of freedom chi-square and a point mass at
zero.

3. Results
3.1. Study Participants. We included a total of 1,383 individuals from the SAFHS on whom genotypic and phenotypic
information was available. The characteristics of the study
participants are summarized in Table 1. Briefly, the mean
age of the participants was 39 years and the majority of
them (60%) were females. At baseline, 15% had T2D, 18%
were hypertensive, ∼39% were obese, and ∼47% had central
obesity. During follow-up of 913 individuals who were initially free of T2D and for whom complete follow-up data
was available, 149 new cases of T2D were detected. Thus, a
total of 357 (∼26%) individuals either had T2D at baseline or
developed it during follow-up. This trait was dubbed “ever
T2D” for the purpose of the present study. The average fasting
and 2-hour postprandial insulin values as well as the HOMAIR and HOMA-𝛽 values indicated that, even in individuals
who did not have T2D at baseline, there was a high likelihood
of insulin resistance (Table 1). Approximately 10% and 2%
participants were using antihypertensive and lipid-lowering
drugs at baseline, respectively.
3.2. SNPs around and within SLC30A8. We included a total
of 118 SNPs contained within a 50 kb region straddling
SLC30A8. These polymorphisms displayed a wide range
of minor allele frequencies from 0.007 to 0.4989 (Supplementary Table 1). In all, 10 (8.47%), 13 (11.02%), and 95
(80.51%) SNPs were found to have a minor allele frequency
of <1%, 1–5%, and >5%, respectively. All of the included
SNPs had call rates exceeding 99% and none of them were
in significant Hardy-Weinberg disequilibrium (defined as
𝑝 < 0.001). The most significant departure from HardyWeinberg equilibrium was observed for the rs7000505 SNP
with a 𝑝 value of 0.0114. Thus, the SNPs included in this
study were fairly common in the Mexican American families
and were genotyped with acceptable levels of errors. In
the context of SLC30A8, only two of the included SNPs
(rs1326634 and rs16889462) were in the coding region and
resulted in a nonsynonymous change at the level of protein.
All other SNPs were either intronic or intergenic. In general,
there was strong linkage disequilibrium among the included
SNPs (Supplementary Figure 1). Using Li and Ji’s method, we
estimated that the 118 SNPs represented only 49 independent
SNPs conditional on the linkage disequilibrium pattern.
3.3. Association of Each SLC30A8 SNP with T2D-Related
Traits. The first step in the association analyses was to
interrogate the association of each SNP with phenotypic traits
related to T2D. Associations were tested using a measured
genotype approach. The results of the analyses are summarized in Figure 1 and detailed in Supplementary Table 1. After
correcting for 49 independent tests, we needed a significance
value of 0.001 (−log10 𝑝 = 3.00) that corresponded with a
global type I error rate of 0.05 for each phenotypic trait studied. All the models were adjusted for age, sex, their first
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and second degree interactions, and the top four principal
components to capture potential population admixture.
We observed (Figure 1, Supplementary Table 1) that, aside
from the rs7817754 SNP that was significantly associated with
incident T2D, no other SNP achieved statistical significance
for association with any of the phenotypic traits studied. The
most significant association with the other phenotypic traits
were as follows: ever T2D, rs7832958 (𝑝 = 0.0086); fasting
glucose, rs6469667 (𝑝 = 0.0071); fasting insulin, rs2938864
(𝑝 = 0.0143); 2-hour glucose, rs1394874 (𝑝 = 0.0018); 2hour insulin, rs1394875 (𝑝 = 0.0016); HOMA-IR, rs2938864
(𝑝 = 0.0019); and HOMA-𝛽, rs6469668 (𝑝 = 0.0040). These
results indicated weak and apparently inconsistent associations of the studied SNPs when considered individually with
T2D-related traits.
We therefore considered the association of each SNP with
all the T2D-related traits using the PS. Given eight traits, 118
SNPs, and a stringent probability criterion of 0.01 we needed
a minimum PS of 4.3010 for statistical significance. We
observed (Figure 2) that a total of 11 SNPs passed this criterion
and showed a somewhat consistent pattern of associations
with the T2D-related traits. These SNPs were (in order
of significance) rs2938864, rs1001646, rs7817754, rs2047962,
rs6469668, rs6469667, rs7832958, rs6469674, rs13269857,
rs3020106, and rs3020119. In the rest of the paper, we
refer to these 11 SNPs as the most significantly associated
(MSA) SNPs. Of note, five (rs2938864, rs7817754, rs6469668,
rs6469667, and rs7832958) of the seven top hits enlisted above
were included in the list of MSA SNPs. However, the list of
MSA SNPs did not include the two coding variants associated
with SLC30A8.
3.4. Interaction of Genetic Variants with Age and Sex. We
investigated if the association of SNPs with T2D-related traits
was interactively altered by age and sex. The results based
on a series of interactive multivariable models are summarized in Table 2 and details are provided in Supplementary
Table 2. As is conventional in interactive models, we used
a relaxed probability criterion of 0.2 to detect evidence of
interaction and corrected it for 49 independent tests for
each phenotypic trait. We found that three SNPs (rs7843392,
rs11985902, and rs17813547) showed significant interaction
with age in regard to ever T2D, incident T2D, and 2-hour
glucose, respectively. To understand the direction of these
interactions we conducted subgroup analyses within the age
and sex strata as shown in Table 2. The rs7843392 SNP was
almost significantly associated with a higher risk of ever
T2D only in those aged ≥45 years. On the other hand,
rs11985902 and rs17813547 polymorphisms were significantly
associated with a significantly increased risk of incident T2D
and higher values of 2-hour glucose in those aged <45 years.
Interestingly, the rs11985902 polymorphism demonstrated a
marginally significant reduction in the risk of incident T2D
in those aged ≥45 years. Lastly, the rs2062947 polymorphism
significantly interacted with sex in the context of ever T2D
and fasting glucose. In both instances, the polymorphism was
associated with a reduced risk in males. Summarily, these
results from interaction analyses demonstrated that only four
(3.38%) polymorphisms showed significant interactions with
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age and sex and none of these four SNPs was included in the
MSA SNPs.

3.5. Combinatorial Associations of SNPs with T2D-Related
Traits: The BQTN Analyses. We conducted the BQTN analyses on the MSA SNPs identified in the previous step. For
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Figure 1: Association of 118 SNPs within and around SLC30A8 with T2D-related traits. Abscissa shows the names and locations of the SNPs
on chromosome 8 and the ordinate shows statistical significance. After correcting for 49 independent tests, we need a −log10 𝑝 value of 2.99
for statistical significance at a global type I error rate of 0.05 for each trait. Full quantitative results are provided in Supplementary Table 1.
Coding variants are indicated in green.
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Figure 2: Probability score for the studied SNPs based on strength of association with eight T2D-related traits. Significantly associated SNPs
are indicated in red colored bars. Coding variants are labeled in green.

each T2D-related trait, we thus evaluated a total of 211 =
2,048 multivariable models (total 16,384 models for eight
traits) that examined all the combinations of the SNPs.
These results are summarized in Table 3 and described in
detail in Supplementary Tables 3–10. Our results showed that
inclusion of one or more SNPs did not reduce the BIC for
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Table 2: SLC30A8-related SNPs showing significant interaction with age or sex.
Trait

Interaction with

Interaction 𝑝

rs7843392

Ever T2D

Age

0.0017

rs11985902

Incident T2D

Age

0.0015

rs17813547

2-hour glucose

Age

0.0024

rs2062947

Ever T2D

Sex

0.0038

rs2062947

Fasting glucose

Sex

0.0031

SNP

Group
Age < 45 y
Age ≥ 45 y
Age < 45 y
Age ≥ 45 y
Age < 45 y
Age ≥ 45 y
Males
Females
Males
Females

Subgroup analyses
𝑁
𝐵
903
−0.45
480
1.16
690
0.20
223
−0.28
837
0.17
305
−0.04
561
−0.47
822
0.08
481
−0.16
689
0.19

𝑝
0.3490
0.0541
0.0334
0.0579
0.0005
0.5832
0.0044
0.4882
0.0745
0.0071

Table 3: Results of BQTN analyses for potential combinatorial associations of SLC30A8-related SNPS with T2D-related traits.
Characteristic
ℎ𝑟2
BIC of best model comparedto the null model
Number of models in window
SNPS in the best model (𝑝)

eT2D
0.65
0.00
0

iT2D
0.66
0.00
0

FG
0.42
0.00
0

FI
0.42
−0.34
1

rs2938864

—

—

rs1001646
rs7817754
rs2047962

—
—
—

rs6469668
rs6469667
rs7832958
rs6469674
rs13269857
rs3020106
rs3020119

2hG
0.37
0.00
0

2hI
0.32
0.00
0

—
—
—

—
—
—

−0.06
(0.54)
—
—
—

—

—

—

—
—
—
—
—
—

—
—
—
—
—
—

—
—
—
—
—
—

HOMA-IR
0.40
−1.75
1

—

—

—
—
—

—
—
—

−0.08
(0.71)
—
—
—

—

—

—

—

—
—
—
—
—
—

—
—
—
—
—
—

—
—
—
—
—
—

—
—
—
—
—
—

HOMA-𝛽
0.26
−1.49
1
—
—
—
—
0.07
(0.68)
—
—
—
—
—
—

eT2D, ever T2D; iT2D, incident T2D; FG, fasting glucose; FI, fasting insulin; 2hG, 2-hour glucose; 2hI, 2-hour insulin; BIC, Bayesian information criterion.

ever T2D, incident T2D, fasting glucose, 2-hour glucose, and
2-hour insulin. For fasting glucose, HOMA-IR, and HOMA𝛽, addition of only one SNP (rs2938864, rs2938864, and
rs6469667, resp.) was associated with a reduced BIC. However, the probability estimates associated with a reduced BIC
indicated that the reduction was not statistically significant.
No other combination improved the BIC.
3.6. Gene Burden Tests for the SLC30A8 Locus. As a final step
in analyses, we examined if joint associations of the studied
variants proffer a significant association of the SLC30A8 as
a whole with the T2D-related traits. In order to maximize
the association signal, we constructed three genetic kinship
matrices that were based on genotyping data from (i) all the
118 SNPs included in this study; (ii) only the two coding
variants; and (iii) the MSA SNPs. Table 4 shows the results
of these analyses. As expected, maximum association signal
was seen when we used the 11 MSA SNPs. The signal was
substantially diminished when the analyses were based on

all the 118 SNPs. Best estimates of the variance component
2
that captured the gene burden effects (columns titled ℎgeff
in Table 4) were seen for incident T2D based on all the 118
SNPs. However, no estimate of the variance component was
statistically significant. These analyses demonstrated that the
variants within and around the SLC30A8 gene did not provide
an association burden to the locus in relation to any of the
eight phenotypic traits studied here.

4. Discussion
The current enthusiasm in the putative role of SLC30A8 in
the pathogenesis of T2D is driven by biological plausibility
as well as association results from large genetic epidemiologic studies in humans. However, the strength of evidence
and the generalizability of the associative observations is
currently unclear. Our study in large pedigrees of Mexican American individuals in San Antonio, Texas, failed to
demonstrate strong or significant patterns of association
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Table 4: Gene burden test for the association of the SLC30A8 locus with T2D-related traits.
Trait

2
ℎgeff

Based on all 118 SNPs
SE
𝑝

2
ℎgeff

Based on 2 coding SNPs
SE
𝑝

2
ℎgeff

Based on 11 MSA SNPs
SE
𝑝

Ever T2D
Incident T2D

0.0000
0.0000

0.0000
0.0000

1.0000
1.0000

0.0005
0.0010

0.0028
0.0052

0.8498
0.8413

0.0080
0.0192

0.0112
0.0223

0.4774
0.3902

Fasting glucose
Fasting insulin

0.0000
0.0000

0.0000
0.0000

1.0000
1.0000

0.0000
0.0000

0.0000
0.0000

1.0000
1.0000

0.0047
0.0031

0.0055
0.0043

0.3946
0.4720

2-hour glucose
2-hour insulin
HOMA-IR

0.0093
0.0037
0.0000

0.0101
0.0067
0.0000

0.3600
0.5791
1.0000

0.0006
0.0000
0.0000

0.0023
0.0000
0.0000

0.8055
1.0000
1.0000

0.0039
0.0021
0.0044

0.0055
0.0043
0.0051

0.4804
0.6288
0.3898

HOMA-𝛽

0.0000

0.0000

1.0000

0.0000

0.0000

1.0000

0.0057

0.0057

0.4102

between SLC30A8 SNPs and several phenotypic traits related
to T2D. The only other study in Mexican Americans from
the Arizona Insulin Resistance Registry also could not find
significant association between SLC30A8 SNPs and T2D [17].
Together, these studies tend to indicate that SLC30A8 variants
are unlikely to be consistently associated with T2D across
different ethnic/racial backgrounds. It is instructive in this
regard that Cheng et al. [7] as well as Cauchi et al. [16]
found ethnic background to be an important contributor to
the between-studies heterogeneity in observed association of
the coding variant rs1326634 with T2D. Our results therefore
proffer a possible but partial explanation for the limited
generalizability of the association between SLC30A8 variants
and T2D. Of note, none of the 11 MSA SNPs found to
be marginally but significantly associated with T2D-related
traits in our studies have been reported to be associated with
disease phenotypes in the ClinVar database (http://www.ncbi
.nlm.nih.gov/clinvar/).
The overall lack of association needs to be considered in
the light of several key aspects related to the SLC30A8-T2D
nexus. First, Cauchi et al. [16] using data from 32 published
studies have shown that the coding variant rs13266634 does
not influence the expression of SLC30A8 in humans. In contrast, data from over 150,000 individuals in the T2D-GENES
consortium [14] shows that rare, loss-of-function variants
that are associated with a significantly reduced expression
of SLC30A8 are also associated with a reduced risk of
T2D across various ethnicities. These confusing findings are
difficult to reconcile. Second, Rungby [30] hypothesizes that
other factors such as age and sex might confound genotypephenotype associations. This hypothesis is supported by
elegant studies in mice [31–34]. Chang et al. have also recently
demonstrated that, in Chinese Han populations, there is a
significant interaction of the rs1366634 polymorphism with
age [35]. In our study we found a negligible interaction of
the SLC30A8 associations with age and sex. The reasons
for these potential interactions and the implication of these
interactions in terms of disease pathogenesis are currently
unknown. Third, there is evidence to show that SLC30A8
expression correlates significantly with the secretion of both
insulin and glucagon [6, 13, 16, 30]. Since insulin and glucagon have opposite actions on glycemic control, it is conceivable that the association of an upstream regulator (such

as SLC30A8) with the overall pathogenesis would be difficult
to detect since its effects on both insulin and glucagon
might partially nullify each other. Fourth, several studies have
demonstrated that there are significant gene-gene and geneenvironment interactions associated with SLC30A8 that can
all mask association of this gene with T2D [36–42]. In total,
these issues make demonstration of association of SLC30A8
variants with T2D both questionable and difficult to show
even if existent.
Before interpreting our results, however, the limitations
of our study must be recognized. First, we used data on 118
SNPs available from various Illumina genotyping platforms.
It is not known whether this coverage adequately captures
the SLC30A8 locus. However, the fact that the most intensely
scrutinized SLC30A8 polymorphism (rs13266634) was not
significantly associated with any T2D-related trait in our
study population provides an indirect measure of internal
consistency of our results. Second, we do not have data on the
expression of SLC30A8 in 𝛽 cells and on the ZnT8 isoforms
and their expression in the study population. Therefore we
cannot comment on the functional importance of the 11
MSA SNPs. Third, our BQTN analyses were extensive but
not exhaustive since it is practically impossible to test for all
the 2118 combinations of the included SNPs. We may have
thus missed some significant SNP-SNP interactions but our
results show that the MSA SNPs were not involved in T2D
pathogenesis in a combinatorial fashion.
Our results have important implications in the continued
quest to conquer T2D. SLC30A8 is an attractive drug target
since development of inhibitors that will reduce the gene
expression is now being pursued as a likely important
discovery [14, 42]. However, whether such interventions will
work in most scenarios will depend on the generalizability of
the results. Our results seem to point towards the possibility
that at least the high-risk Mexican American individuals
are unlikely to benefit by an intervention that is based on
inhibition of SLC30A8. Even if our interpretations were to
be based on the 11 MSA SNPs, we find that only 1-2% of
the variability in T2D-related traits may be attributable to
the SLC30A8 locus (Table 4). These findings beckon that
a comprehensive understanding of the role of SLC30A8 is
needed before an interventional leap based on this gene is
considered to prevent or treat T2D.
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